PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced that it has expanded the industry’s largest reagent product portfolio for the detection and analysis of protein kinase activity to 310 assays.
The seven new LANCE® Ultra assay products – three substrates and four detection antibodies – further increase PerkinElmer’s leading position in protein kinase research offerings. This enables researchers to address a wide range of therapeutic targets including cancer, central nervous system disorders, cardiac dysfunction and metabolic diseases. All LANCE Ultra assay products are validated against commercially available protein kinases, giving researchers peace-of-mind that their assays will produce accurate and reproducible results.
“PerkinElmer is pleased to announce the widest and most extensive range of high quality kinase assays available for pharmaceutical screening and profiling,” said Martina Bielefeld-Sevigny, PhD, vice president and general manager, Drug Discovery and Research Reagent Solutions, Bio-discovery, PerkinElmer. “The introduction of our new LANCE assays is an integral component of our goal to continue to grow and maintain the premier industry portfolio for cellular and biochemical assays for protein kinase analysis. In addition, the more optimal the reagent offering available to kinase researchers, the less time spent in assay development, allowing more time to be spent conducting high value screening and profiling screening.”